"I have also long-suspected that Starpharma have had a deliberate strategy to release the (monotherapy) results of the three phase 2 trials (or, at least two of them) quite close to one another, to maximise the collective impact of the releases as 'proof of concept' of the DEP platform, to give them a stronger position to negotiate deals. Timing the release of top-line results so they are soon-after followed by presentations at conferences would also make sense, in terms of getting good media and industry exposure"
Fantastic idea, Gumnut70. However. I think that this would be a breach of the ASX's continuous disclosure requirements. I hope that your other optimistic musings about SPL are not fantasies. These SPL threads appear to be riddled with unrealistic posts from serial fantasists.
In my opinion, formulating good strategies is not one of SPL's strengths, so fantasising about SPL's strategies is a waste of time. I think that it is realistic to hope for only those things that SPL has proven that it can do (apart from its repeatedly proven inability to monetise its products).
- Forums
- ASX - By Stock
- SPL
- Optimism
Optimism, page-35
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $38.39M |
Open | High | Low | Value | Volume |
9.2¢ | 9.3¢ | 9.1¢ | $176.4K | 1.915M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 439927 | 9.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.3¢ | 95900 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 439927 | 0.092 |
2 | 71451 | 0.091 |
7 | 98853 | 0.090 |
3 | 114179 | 0.089 |
2 | 45464 | 0.088 |
Price($) | Vol. | No. |
---|---|---|
0.093 | 95900 | 2 |
0.094 | 152000 | 2 |
0.095 | 32403 | 2 |
0.096 | 104177 | 1 |
0.098 | 11506 | 1 |
Last trade - 11.49am 21/10/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online